Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Cat.No. : CSC-RR0251 Host Cell: A375
| Cat. No. | CSC-RR0251 |
| Description | Luc Reporter Cell Line-A375 is engineered to stably overexpress luciferase reporter gene. It is an ideal positive control for use in bioluminescence assays. In addition, A375 cells form tumors post implantation into immunocompromised mice. The in vivo growth of these tumors can be monitored using bioluminescent imaging. |
| Background | The Luc Reporter Cell Line in A375 cells is a model that uses luciferase to monitor gene expression and cellular activity. A375 is a human malignant melanoma cell line that is used for studying the biology of melanoma and for drug development. The stable expression of luciferase in A375 cells allows for the quantification of gene expression and cellular activity in response to various stimuli, such as growth factors, cytokines, or potential therapeutic agents. This cell line is valuable for investigating the molecular mechanisms underlying melanoma progression and for evaluating the efficacy of potential therapeutic strategies against melanoma. |
| Gene | Luciferase |
| Host Cell | A375 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Protein localization 3. Drug screening and toxicology 4. Live cell imaging |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Melanoma, the most aggressive skin cancer, often develops resistance to targeted therapies, particularly those aimed at BRAFV600E. Researchers focused on tryptanthrin (Tpn), a compound with notable anti-tumor effects, which targets the microphthalmia-associated transcription factor-M (MITF-M). This transcription factor plays a crucial role in melanoma cell survival. By down-regulating MITF-M, Tpn disrupts critical signaling pathways, demonstrating significant potential in reducing tumor growth and metastasis in murine models using A375-Luc+ cells. The efficacy of Tpn was assessed through live imaging and histological analysis, revealing a marked decrease in tumor bioluminescence and alteration in tumor cell characteristics.
Figure 1. The researchers utilized live imaging with luciferin to assess Tpn's impact on melanoma tumor growth in A375-Luc+ xenograft models, comparing treatment and control groups. (Shabna A, et al., 2022)
Creative Biogene's Luc Reporter Cell Line-A375 offers a powerful tool for studying melanoma therapies similar to Tpn. This stable cell line allows for real-time monitoring of tumor dynamics and treatment responses, enabling researchers to explore innovative therapeutic strategies.
A: The Luc Reporter Cell Line-A375 can be genetically modified to incorporate target sequences for RNA interference or CRISPR/Cas9 systems. By treating the cells with small interfering RNAs (siRNAs) or CRISPR reagents designed to target specific genes, researchers can assess the efficacy of these gene silencing approaches by measuring changes in luciferase activity. This provides a quantitative readout of gene knockdown efficiency and can help optimize the conditions for these techniques in melanoma research.
A: When studying the effects of epigenetic modifications on gene expression using the Luc Reporter Cell Line-A375, it is important to consider factors such as the choice of epigenetic drugs, the duration of treatment, and the timing of luciferase assays. Researchers must also ensure that the epigenetic changes are specifically targeting the gene of interest and not affecting the luciferase reporter itself. Additionally, the use of appropriate controls, including untreated cells and cells treated with epigenetic modifiers known to affect luciferase expression, is crucial for validating the results.
A: The Luc Reporter Cell Line-A375 can be used to study the interplay between various signaling pathways in melanoma by manipulating the activity of one pathway and observing the effects on luciferase activity, which reflects the transcriptional output of the target gene. This can help elucidate how different signaling pathways coordinate to regulate melanoma cell behavior and contribute to tumor progression.
A: The Luc Reporter Cell Line-A375 can be employed in preclinical studies to evaluate the safety and efficacy of new anti-melanoma drugs. By treating the cells with the test compounds and measuring changes in luciferase activity, researchers can assess the compounds' impact on melanoma cell growth and survival. This cell line can also be used to study the potential side effects of the drugs on non-target cells, providing valuable information for the drug development process.
A: The Luc Reporter Cell Line-A375 provides a platform for investigating the transcriptional regulation of genes that are implicated in melanoma progression. By introducing regulatory elements or transcription factors associated with melanoma into this cell line, researchers can monitor the changes in luciferase activity, which serves as a proxy for gene expression levels. This can help identify key regulatory mechanisms and potential therapeutic targets for melanoma treatment.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The A375 Luc Reporter Cell Line allows for sensitive detection of luciferase activity, which is crucial for measuring low levels of gene expression or cellular responses.
United States
09/15/2023
The cell line enables monitoring of real-time cellular responses to various stimuli, as luciferase activity can be measured frequently without cell lysis.
United Kingdom
02/27/2021
The luciferase reporter in A375 cells facilitates single-cell analysis, which can reveal cell-to-cell variability in gene expression or signaling responses.
United States
10/24/2023
The A375 Luc Reporter Cell Line is suitable for time-course experiments, as luciferase activity can be repeatedly measured from the same cell population.
Germany
12/10/2022
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.